Relay Therapeutics (NASDAQ: RLAY) has announced that it will be unveiling its third quarter financial results on Wednesday 6th November 2024. The disclosure is planned to occur after market close.
The financial experts on Wall Street are predicting that the concern will likely report an estimated $0.77 loss per share for the third quarter. Additionally, it is anticipated that the company will reveal a $0.08 million revenue during the quarter.
Wall Street analysts have shared their forecasts for the company's annual performance, predicting a total revenue of $10.16 million. Additionally, they expect the company to post loss of $2.84 per share for the fiscal year.
In the preceding quarter of the previous year, the company shared its financial results, revealing that it had loss of $0.54 per share.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.69 | +14.8% | 0.00 M | -100.0% |
| Q1 2024 | $-0.62 | +20.5% | 10.01 M | +4,327.9% |
| Q4 2023 | $-0.67 | -19.6% | 0.00 M | -100.0% |
| Q3 2023 | $-0.54 | +28.9% | 25.20 M | +7,226.2% |
| Q2 2023 | $-0.81 | -14.1% | 0.12 M | -67.4% |
| *Growth on year-over-year basis | ||||
Relay Therapeutics (RLAY) shares traded as low as $5.63 and as high as $6.00 on a day volume of 1.20 million shares, closed Friday's regular trading session at $5.84, an upturn of 3.55 percent.
